|
5 Companies |
|
3 Products |
|
3 Products |
|
0 Mechanisms of Action |
|
0 Trials |
|
15 News |
|
- Crysvita (burosumab) / Ultragenyx, Kyowa Kirin
Trial primary completion date: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia (clinicaltrials.gov) - Mar 3, 2017
P1, N=15, Completed, Sponsor: Kyowa Hakko Kirin Co., Ltd
Trial primary completion date: Dec 2015 --> Jun 2015
- Fortical (calcitonin salmon recombinant) / Enteris
Trial completion: Calcitonin for Treating X-linked Hypophosphatemia (clinicaltrials.gov) - May 25, 2016
P=N/A, N=21, Completed, Sponsor: Yale University
Trial primary completion date: Dec 2015 --> Jun 2015 Recruiting --> Completed
- | Crysvita (burosumab) / Ultragenyx, Kyowa Kirin
Trial completion: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia (clinicaltrials.gov) - Mar 18, 2016
P1, N=15, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Recruiting --> Completed Active, not recruiting --> Completed
- cinacalcet HCl / Generic mfg.
Trial primary completion date: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) (clinicaltrials.gov) - Nov 9, 2015
P1, N=1, Terminated, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2016
- Crysvita (burosumab) / Ultragenyx, Kyowa Kirin
Enrollment closed: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia (clinicaltrials.gov) - Aug 19, 2015
P1, N=15, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
Trial primary completion date: Oct 2015 --> Oct 2016 Recruiting --> Active, not recruiting
- cinacalcet HCl / Generic mfg.
Enrollment change, Trial termination: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) (clinicaltrials.gov) - Jul 9, 2015
P1, N=1, Terminated, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting --> Active, not recruiting N=17 --> 1 | Recruiting --> Terminated
- Fortical (calcitonin salmon recombinant) / Enteris
Trial primary completion date: Calcitonin for Treating X-linked Hypophosphatemia (clinicaltrials.gov) - Feb 27, 2015
P=N/A, N=20, Recruiting, Sponsor: Yale University
N=17 --> 1 | Recruiting --> Terminated Trial primary completion date: Dec 2014 --> Aug 2015
- | Crysvita (burosumab) / Ultragenyx, Kyowa Kirin
New P1 trial: A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia (clinicaltrials.gov) - Jul 8, 2014
P1, N=15, Recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
- Fortical (calcitonin salmon recombinant) / Enteris
Trial primary completion date: Calcitonin for Treating X-linked Hypophosphatemia (clinicaltrials.gov) - Jun 13, 2014
P=N/A, N=20, Recruiting, Sponsor: Yale University
Trial primary completion date: Dec 2014 --> Aug 2015 Trial primary completion date: Dec 2013 --> Dec 2014
- | Phosribbon Combination Granules (sodium phosphate monobasic monohydrate) / Zeria Pharma
Enrollment change: Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets (clinicaltrials.gov) - Sep 29, 2013
P3, N=16, Completed, Sponsor: Zeria Pharmaceutical
Trial primary completion date: Dec 2013 --> Dec 2014 N=10 --> 16
- || Phosribbon Combination Granules (sodium phosphate monobasic monohydrate) / Zeria Pharma
Trial completion: Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets (clinicaltrials.gov) - Sep 29, 2013
P3, N=16, Completed, Sponsor: Zeria Pharmaceutical
N=10 --> 16 Active, not recruiting --> Completed
- Enrollment change: Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients (clinicaltrials.gov) - Jun 11, 2013
P=N/A, N=26, Completed, Sponsor: Rambam Health Care Campus
Active, not recruiting --> Completed N=40 --> 26
- Trial completion: Assessment Of Vitamin D Role In The Pathogenesis Of Asthma In Vitamin D Resistent Patients (clinicaltrials.gov) - Jun 11, 2013
P=N/A, N=26, Completed, Sponsor: Rambam Health Care Campus
N=40 --> 26 Active, not recruiting --> Completed
- cinacalcet HCl / Generic mfg.
New P1 trial: Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets) (clinicaltrials.gov) - Dec 11, 2012
P1, N=17, Recruiting, Sponsor: National Institute of Dental and Craniofacial Research (NIDCR)
- | Crysvita (burosumab-twza) / Ultragenyx, Kyowa Kirin
Trial completion: A Study of KRN23 in X-linked Hypophosphatemia (clinicaltrials.gov) - Dec 5, 2011
P1, N=42, Completed, Sponsor: Kyowa Hakko Kirin Pharma, Inc.
Active, not recruiting --> Completed Recruiting --> Completed